Organizational Disclosures

about the aan

Below is a breakdown of industry contribution towards the consolidated revenue of the Academy (American Academy of Neurology and American Academy of Neurology Institute). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the health care sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).

2022 External (Industry) Support

  • Total Industry Revenue: $9,465,419
  • Percentage of Total Academy Revenue: 14%
  • Educational Grants: $453,000
  • Sponsorship: $5,077,794
  • Exhibit Space: $2,244,625
  • Industry Roundtable Membership Dues: $1,690,000

Total contribution by company in 2022 (Greater than $100K):

AbbVie, Inc.

Actelion Pharmaceuticals Ltd..

Alexion Pharmaceuticals

Allergan, Inc.

Amgen

ANI Pharmaceuticals, Inc.

argenx

AveXis, Inc.

Biogen

Biohaven Pharmaceuticals

Bristol Myers Squibb

Eisai Inc.

Eli Lilly and Company

EMC Sorono, Inc.

Genentech

Idorsia Pharmaceuticals US, Inc.

Lundbeck

Neurocrine Biosciences

Novartis Pharmaceuticals

Sanofi Genzyme

Sarepta Therapeutics

SK life science

Supernus Pharmaceuticals, Inc.

TG Therapeutics

UCB, Inc.

Viela Bio

View the Principles Governing Academy Relationships with External Sources of Support

View the Council of Medical Specialty Societies Code for Interactions with Companies